Pleuromutilin is a tricyclic diterpenoid antibiotic that serves as the precursor for semisynthetic pleuromutilin derivatives. It exhibits broad-spectrum antibacterial activity against most Gram-positive bacteria, mycoplasmas, and some Gram-negative bacteria by inhibiting bacterial protein synthesis through binding to the 50S ribosomal subunit and suppressing peptidyl transferase activity.
Pleuromutilin derivatives have been developed for both veterinary and human use:
- Tiamulin and valnemulin are used exclusively in veterinary medicine for treating swine dysentery, pneumonia, and other respiratory and gastrointestinal infections in livestock and poultry; valnemulin is particularly effective for mycoplasma-induced pulmonary diseases due to its high lung concentration.
- Retapamulin is approved for human topical use in treating impetigo caused by Staphylococcus aureus and Streptococcus pyogenes in adults and children aged 9 months and older.
- Lefamulin (BC-3781), a novel pleuromutilin derivative, is under development as the first systemic (intravenous or oral) pleuromutilin antibiotic for human use, intended for the treatment of community-acquired bacterial pneumonia (CABP).